Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Characterization of Macroprolactinemia

This study has been completed.
Sponsor:
Information provided by:
Kansai Medical University
ClinicalTrials.gov Identifier:
NCT00436111
First received: February 15, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed.

We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.


Condition
Hyperprolactinemia

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Kansai Medical University:

Study Start Date: January 2005
Estimated Study Completion Date: December 2006
  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Clinical diagnosis of hyperprolactinemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436111

Locations
Japan
Kansai Medical University
Osaka, Japan, 570-8506
Sponsors and Collaborators
Kansai Medical University
Investigators
Study Chair: Naoki Hattori, M.D., Ph.D. Department of Pharmacology, Kansai Medical University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00436111     History of Changes
Other Study ID Numbers: KK-2007-1
Study First Received: February 15, 2007
Last Updated: February 15, 2007
Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Kansai Medical University:
hyperprolactinemia
autoantibody

Additional relevant MeSH terms:
Hyperprolactinemia
Brain Diseases
Central Nervous System Diseases
Endocrine System Diseases
Hyperpituitarism
Hypothalamic Diseases
Nervous System Diseases
Pituitary Diseases

ClinicalTrials.gov processed this record on November 25, 2014